我們已在上線！進一步了解

Adaptive Biotechnologies

ADPT

市值 US$38.3億

24.02 USD

-1.56

6.1%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

23.75

-0.27

1.12%

1天

-6.1%

5天

-8.7%

1個月

-13.19%

3個月

8.69%

6個月

70.6%

今年迄今

50.97%

1年

39.09%

5年

-24.89%

10年

-40.4%

關於： Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

員工： 624

醫療保健診斷與研究

新聞

正面

中性

負面

市場情緒 3個月

正面 26.7%

中性 66.7%

負面 6.7%

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scotland, on behalf of IMS and the International Myeloma Working Group (IMWG).

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted significant updates to the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma that further establish highly sensitive minimal (or measurable) residual disease (MRD) assessment as an important tool in myeloma care.

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science

Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode

Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses.

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Zacks Investment Research

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

查看新聞排名

價格圖表採用Lightweight Charts™實作